Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Recombinant CTLA-4 Extracellular Domain Fc fragment (human IgG1 isotype) Protein

Catalog No.: YR0045

Basic Information

Molecular Weight

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SDS-PAGE

Background

Abatacept (trade name Orencia, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). Abatacept inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids.The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.

Reported Applications

Functional assays,and those assays for studying biological pathways affected by abatacept.

Immunogen Information

Clone
Abatacept Biosimilar

Isotype
Human IgG1 Fc

Immunogen
/

RecommendedIsotype Control(s)
In Vivo Grade Recombinant Human IgG1 Fc Protein

Recommended Dilution Buffer
1×PBS pH 6.8 to 7.4

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn

Product Information

Production
Purified from cell culture supernatant in an animal-free facility

Purification
Protein A or G purification

Storage
Store at -20℃